Loading...

LEXX LEXARIA BIOSCIENCE CORP Product Launches 8-K Filing

LXR

LXX

LEXARIA BIOSCIENCE CORP

(LEXX)

2023 8-K

Fundraising Update

Sales Agreement Termination

Product Expansion

Equity Offerings

Sales Agreement Update

Shareholder Meeting

Management Change

Project Agreement

Director Nominations

Management Change

Stock Sale Agreement

Resignation of CFO and Init...

Warrant Exercise Agreement

Annual Shareholder Meeting

Amendment of Material Defin...

Appointment of CFO

FDA Approval for Clinical T...

Securities Purchase Agreement

IND Application for Hyperte...

Regulation FD Disclosure

Compliance and Warrant Exer...

Shareholder Meeting and Oth...

Securities Purchase Agreement

Licensing Amendment and New...

New Product Launches

Management Changes

Entry into a Material Defin...

Investment Offering

Annual Shareholder Meeting

Regulation FD Disclosure

External Links:

Lexaria Bioscience Corp. has announced the recent issuance of US patents for the usage of its DehydraTECH technology, aimed at the treatment of hypertension and for use alongside nicotine molecules in sublingual delivery formats. These patents will broaden Lexaria's commercial opportunities in both the pharmaceutical and consumer markets.

AI Assistant

LEXARIA BIOSCIENCE CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.